Title: The Role ACT Score in Mepolizumab Discontinuation

*Neha Solanki, MD[1], Brittany Beck[2], Monica Labadia[2], Kevin Smith[2], Laura Peterson[2], Stephanie King, MSN,
RN[1], Sarah Micklewright, PA-C[1], Emily Pennington, MD[1], Sobia Farooq, MD[1], Peng Zhang, MD[1], Mark
Aronica, MD[1], Joe Zein, MD, PhD[1,2], Sumita Khatri, MD, MS[3], Suzy Comhair, PhD[2], Serpil Erzurum, MD[1,2]

[1]Respiratory Institute, Cleveland Clinic, [2]Lerner Research Institute, Cleveland Clinic, [3]National Heart, Lung,
and Blood Institute

Abstract:

Background: Mepolizumab is a therapy for severe asthma. However, studies on mepolizumab with external
validity and diverse population from the US are lacking. There is little knowledge of the characteristics of
people that discontinue mepolizumab in clinical care.

Objective: To investigate the real-world efficacy and time to clinical discontinuation of mepolizumab, we
evaluated individuals with asthma started on mepolizumab at the Cleveland Clinic. We hypothesized that there
are characteristics that distinguish which patients would remain on mepolizumab and which patients would
discontinue the medication.

Methods: Between 2016 and 2022, patients who started on mepolizumab consented to be assessed over 18
months. At baseline, a questionnaire including demographic and medical history was collected. Laboratory
findings such as ACT score, $F_E NO$ (Fractional Excretion of Nitric Oxide), and spirometry were recorded. At the
conclusion of the observation period, the participants were divided into two categories: Group A and Group B.

Results: Group B [N=28] discontinued mepolizumab ($P < 0.05$) at an average of 5.8 months (SD 4.2 months).
Group A [N=129] stayed on the therapy for at least 1 year. A participant with an ACT score less than 13 has an
odds ratio of 6.64 (95% CI, 2.1 – 26.0) of discontinuing mepolizumab therapy. For a male, the odds of
discontinuing mepolizumab therapy is 3.39 (95% CI, 1.1 – 11.2).

Conclusion: In this real-world study, we find that high eosinophil count may not be adequate in screening
which individuals will benefit from mepolizumab. Up to 17% of patients fail therapy within 6 months, with male
sex and low ACT score increasing risk of mepolizumab discontinuation at Cleveland Clinic.

Abstract Word Count: 263

Word Count: 2862

Keywords: Asthma, asthma control, mepolizumab

Abbreviations:

**ACT = asthma control test; AUC = area under curve; BMI = body mass index; CAD = coronary artery
disease; CBC = complete blood count; CHF = congestive heart failure; DBP = diastolic blood pressure;
Federal Drug Administration = FDA; $F_E NO$ = fractional excretion of nitric oxide; FEV_1 = forced
expiratory volume in one second; GERD = gastroesophageal reflux disease; GINA = Global Initiative for
Asthma; GSK = GlaxoSmithKline; ICS = inhaled corticosteroids; IQR = interquartile range; IRB=
Institutional Review Board; LABA = Long-acting beta agonist; µL = microliters; ROC = receiver
operating curve; SBP = systolic blood pressure; WBC = white blood cell.**

Introduction:

People with severe and uncontrolled asthma experience the highest impact on quality of life and accompanying morbidity from asthma. Severe asthma, which is uncontrolled asthma despite adherence to high dose inhaled corticosteroids (ICS) and long-acting beta agonist treatment (LABA), is present in 5%-10% of people with asthma (1, 2). Caregivers have new and exciting management options for steroid-sparing medications including treatment with monoclonal antibodies also known as biologic agents that target immunoglobulin E (IgE), interleukin 5, interleukin-5 receptor, or interleukin-4 receptor (3). The introduction of biologic therapy to the treatment of severe asthma represents an opportunity to carry out phenotype-specific intervention, reinforcing the need for precision in diagnosis (1). Though the Global Initiative for Asthma (GINA) does include a decision tree for how to choose a biologic agent for an individual with severe asthma, many individuals remain uncontrolled and can remain on a biologic agent for longer than necessary (2). People with severe and uncontrolled asthma experience the highest impact on quality of life and accompanying morbidity from asthma. Additionally, according to GINA, the cost of treating individuals with severe asthma is higher when compared to the cost of treating the general population for asthma (2, 4), which further underscores the possible benefits for precision medicine in asthma control and healthcare costs.

GlaxoSmithKline's (GSK) mepolizumab, a humanized, interleukin-5 antagonist monoclonal antibody, received approval from the US FDA (Federal Drug Administration) in 2015 for add-on treatment in adults with severe eosinophilic asthma (5). The clinical trials that evaluated mepolizumab in patients with asthma included three double-blind, randomized, placebo-controlled studies, including DREAM (Dose Ranging Efficacy And safety with Mepolizumab in severe asthma; NCT01000506), the Phase III MENSA (MEpolizumab as adjuNctive therapy in patients with Severe Asthma; NCT01691521) trial, and SIRIUS (SteroId ReductIon with mepolizUmab Study; NCT01691508) (5). The DREAM trial showed that a baseline blood eosinophil count and increased exacerbation frequency in the previous year were associated with good response to mepolizumab. The confirmatory trials required patients to have a blood eosinophil level greater than or equal to 150 cells/µL at screening or blood eosinophil

levels greater than or equal to 300 cells/μL within one year of enrollment (6). SIRIUS, a 24-week clinical trial, demonstrated that mepolizumab has a significant glucocorticoid-sparing effect compared with placebo (6). In patients with baseline eosinophil counts greater than or equal to 150 cells//μL, the DREAM, MENSA, and MUSCA (Mepolizumab adjUnctive therapy in subjects with Severe eosinophiliC Asthma; NCT02281318) trials demonstrated that mepolizumab treatment reduces exacerbations, increases forced expiratory volume in one second (FEV_1) and improves asthma control and quality of life (5). While clinical trials are pivotal for FDA-approval of new therapies, real world applications of medicines can often reveal different outcomes than in prospective blinded trials (7).

To assess real-world effects of mepolizumab, Glaxo Smith Kline (GSK) funded REALITI-A (REAL world effectiveness of mepolizumab in patient care – Asthma), a large prospective study with 368 participants. REALITI-A demonstrated a meaningful reduction in daily maintenance oral corticosteroid dose for people with asthma and a decrease in the rate of exacerbations. However, there was not a difference shown for FEV_1 (forced expiratory value in 1 second) % (5). Observational real-world cohorts from Europe also showed that mepolizumab reduces prednisone dependence and improves asthma control (8-10). Israeli and Australian studies demonstrate an additional FEV_1% improvement (11, 12). The results from this real-world study suggest that more data are needed regarding the effects of mepolizumab on FEV_1% and the time to mepolizumab's clinical failure for a person with very severe asthma.

To further investigate the real-world efficacy of mepolizumab, time to discontinuation of mepolizumab and identification of clinical traits of those who remain on mepolizumab, we evaluated people with asthma treated with mepolizumab at the Asthma Center of Cleveland Clinic over 6 years. We hypothesized that there may be baseline characteristics that distinguish which patients will respond to mepolizumab and the characteristics of the type of response, including better asthma control, lower corticosteroid dose, and better lung functions.

Methods:

Baseline Characteristics

Cleveland Clinic's biologic registry includes individuals on omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, and tezepelumab. An asthma specialist assessed eligible participants in the registry and prescribed mepolizumab based on standard U.S guidelines at the time of study. These guidelines included an absolute blood count eosinophil ≥ 150 cells/ µL or corticosteroid dependence and clinical evidence of uncontrolled asthma as demonstrated by two or more asthma exacerbations requiring prednisone, one or more hospitalizations or emergency medical visits or poor symptom control while being on an inhaled corticosteroid and a long-acting beta-agonist. Between 2016 and 2022, we consented 199 people who were prescribed mepolizumab by their provider. The Institutional Review Board (IRB # 8351) at Cleveland Clinic approved the study protocol and procedure.

Longitudinal Assessment

The study team assessed each participant at baseline visit prior to first dose of mepolizumab, and then at 3 months, 6 months, 12 months, and 18 months (Figure 1). At the baseline visit, our team collected a questionnaire which included demographic information, asthma history, medical history, review of systems, asthma medications, and healthcare utilization from each participant (Figure 1). We also recorded peak flow, ACT score, $F_E NO$, spirometry and CBC, and we conducted similar assessments of the participants in subsequent visits.

Outcomes

The outcome of this retrospective study was discontinuation of mepolizumab therapy based on lack of clinical response, which was determined by the asthma specialist and informed by the patient's

perspective and the provider's medical reasoning. After 18 months of serial assessments, participants

who started mepolizumab were divided into two categories: Group A and Group B. We defined Group

A participants received mepolizumab for at least six months or received mepolizumab for 18 months

without a change in therapy. Group B participants stopped the therapy within 6 months or had a

clinical need to switch to a different biologic therapy within 18 months. Chart review excluded

participants who stopped mepolizumab therapy due to other reasons .

Statistical analysis

We performed all analyses with R, version 4.1.2 (R Project for Statistical Computing, Vienna, Austria),

and we reported results as mean with standard deviation or median with interquartile range

depending on whether the value was parametric or non-parametric. For the descriptive analysis, we

used student's t-test or Kruskal-Wallis test to compare participants on mepolizumab to those on other

biologics and to compare mepolizumab responders and non-responders. Categorical variables were

analyzed using chi-squared tests. Comorbidities that that have 10% or higher missing data were

excluded. Several columns that had over 10% of "missing" values were excluded.

We used a Kaplan-Meier curve to compare time on the drug for mepolizumab responders and non-

responders. Each responders' time was censored after 18 months. When data were censored, the

total time on mepolizumab for a subject cannot be accurately determined past a certain date. Log

rank was used to calculate P for the Kaplan-Meier curve. A receiver operative curve (ROC) with C-

index was used to determine optimal cutoff for discrete variables with $P < 0.05$ between responders

and non-responders. For the inferential analysis, binomial logistic regression was utilized to obtain

odds ratio with confidence intervals. In this analysis, less than 4% of data were missing and were

deemed missing completely at random.

Results:

Of the participants who started on mepolizumab ($n = 199$), the top reason for exclusion is lack of recorded follow-up visits ($n = 27$). Participants ($n = 15$) are excluded for medication side effects, loss to follow up, or change in medication indication (Figure 2a). 157 (70.4%) of the participants who started on mepolizumab at their baseline visits are included in this analysis (Figure 2b). The group that started mepolizumab and the group that started other biologic agents have similar baseline demographic characteristics and medical comorbidities (Table 1) except for a higher prevalence nasal polyps ($n = 69$ versus [vs] $n = 16$, $P < 0.05$) and sinusitis ($n = 112$ vs $n = 30$, $P < 0.05$) in participants placed on mepolizumab. Participants starting mepolizumab are also more prednisone dependent ($n = 98$ vs $n = 24$, $P < 0.001$). There are no differences in asthma control score, eosinophil counts, and daily oral prednisone use between the two groups (Table 1).

For the participants placed on mepolizumab ($n = 157$), there is gradual attrition over visits 3, 6, 12, 18

months (Figure 3). Despite attrition, median ACT scores improve over sequential visits on

mepolizumab ($P < 0.05$) (Figure 4-A). FEV_1 improves rapidly in most individuals between the baseline

visit and 3 months, however it is not sustained ($P < 0.05$) (Figure 4-B). There is a striking decline in

prednisone use between visit 1 and subsequent visits ($P < 0.05$) (Figure 4-C).

Of the 157 individuals on mepolizumab, 129 are classified as Group A and 28 as Group B (Table 2).

Group B participants are on mepolizumab therapy ($P < 0.05$) for an average of 5.8 months (standard

deviation [SD] 4.2 months) (Figure 5). Participants in Group A demonstrated a higher ACT score at

each subsequent visit (Figure 6A); whereas participants in Group B did not demonstrate a change in

ACT score through subsequent visits (Figure 6B).Group B participants have lower median baseline

ACT of 9 (interquartile range [IQR], 4) compared to 13 (IQR, 9) for responders ($P < 0.05$) (See Figure

7). There are no other differences between the baseline characteristics of the two groups (Table 2). Sub-analysis of people with nasal polyps demonstrates that there is no difference in the people who discontinue mepolizumab and those who stay on the medication (Table 3).

Based on the observed difference in ACT of the groups, the area under the curve (AUC) of the receiver operative curve analysis was 0.68 for an ACT cutoff score of 13 (Figure 8). Binomial logistic regression controlled for age, BMI (Body Mass Index), F_ENO, and eosinophils show that for a participant who has an ACT score less than 13, the odds ratio of being in Group B is 6.64 (95% CI, 2.1 – 26.0) (Figure 9). Men have an odds ratio of 3.39 (95% CI, 1.1 – 11.2) for being in Group B (Figure 9)

Discussion:

Utilizing this real-world cohort of people with severe asthma, we find that most people on mepolizumab demonstrate clinical improvement shown by a decrease in ACT score by 18 months, a decrease in prednisone use as soon as 3 months, and an initial increase in FEV_1% by 3 months. Our findings also corroborate the REALITI-A trial and other real-world studies, but unlike others, this study is sponsored in part by NIH. When compared to the cohorts on other biologic therapy, the mepolizumab cohort comprises this registry's longest and most complete longitudinal data. This study, which is the largest US real-world mepolizumab to date, shows that despite having eosinophils ≥ 150 cells/µL and history of recurrent asthma exacerbations, male sex or a person with severe asthma who has an ACT score < 13 is more likely to discontinue mepolizumab therapy. Our findings also show that if mepolizumab is discontinued, the discontinuation will occur within 6 months of starting the drug; those that stay on mepolizumab and demonstrate an improvement in ACT score are on mepolizumab for at least an average of 1 year. The results suggest that poorly controlled asthma at baseline and men with severe asthma may have a different biologic endotype less responsive to IL-5 therapy. A sub-analysis of Group B including those individuals initially excluded for side effects

demonstrates that sex remains a critical variable for discontinuing mepolizumab at 6 months.

Additionally, those with a lower baseline ACT score still are more likely to discontinue mepolizumab at

6 months. These findings in the intention-to-treat sub-analysis bolster the initial findings (Table 4).

Participants of Group B may have a complex neutrophilic or pauci-granulocytic mechanism for their

asthma because Type 2 (T2) inflammation-mediated asthma responds well to mepolizumab (13).

Another possibility is that their asthma may be not controlled well at baseline. Predictive biomarkers

for response to mepolizumab treatments so far include blood eosinophil counts as the strongest

predictor for the reduction in exacerbation rates with mepolizumab compared to placebo (14).

However, in our study, eosinophil counts are similar among responders and non-responders. The

Australian Mepolizumab Registry did find that higher blood eosinophil levels and a better baseline

Asthma Control Questionnaire (ACQ-5) predicted a superior clinical response to mepolizumab (11).

Regarding sex as a risk factor, 31% of the participants in our study on mepolizumab are male. While

most of the participants in our study are female, males were found to have an odds ratio of 3.39 of

failing mepolizumab therapy. The Australian Mepolizumab Registry also found that males were more

likely to fail mepolizumab therapy (11). Sex hormones play a role in asthma severity, and androgens

such as testosterone may reduce asthma incidence and symptoms (15). Therefore, the finding that

males have higher odds of failing mepolizumab therapy is unexpected and may suggest underlying

sex-based mechanism for this subset.

For our study, the median $FEV_1\%$ improves by 3 months on the therapy. Most people also have a

decrease in prednisone use by the third month. Therefore, we expected $FEV_1\%$ to stay consistent or

continue improving after visit 3, but we do not find any remarkable differences past the third month on

mepolizumab. Therefore, while there may be an initial improvement in $FEV_1\%$ by the third month, the effect is not long-lasting. Pre-bronchodilator $FEV_1\%$ is lower at baseline for participants (though $P > 0.05$) who are clinical non-responders compared to clinical responders. If the study had higher power, it is possible that this difference would become more pronounced. REALITI-A does not show a difference shown for $FEV_1\%$ (5), but Israeli and Australian studies demonstrate an $FEV_1\%$ improvement (11, 12).Obesity, which causes changes to normal lung physiology, innate immune function, and changes in the gut microbiome, is a major risk factor and disease modifier in asthma for adults (16). The BMI values of people on mepolizumab trend higher than the BMI values of people placed on other biologics (32.1 [9.7] vs 30 [12.1] ($P = 0.171$), and the BMI values of Group B trend higher than the BMI values of Group A (32.5 [7.8] vs 31 [12] ($P = 0.513$). Obesity causes mechanical changes such as lung compression and reduction in lung volume (16). As BMI increases, there is a higher risk for airway hyperreactivity (17). Additionally, the Western dietary pattern, which promotes obesity, might also affect the development of asthma via changes in gut microbiome (16).

While this study has many strengths such as strong external validity because it is a real-world study and has a diverse demographic population, it has three limitations. In a real-world study, there are no controls and no randomization. The first limitation in our study is that participants who started on mepolizumab compared to those that started on other biologic agents have higher a prevalence of chronic rhinosinusitis with nasal polyposis (CRSwNP). After the randomized controlled trial, SYNAPSE, mepolizumab was approved for nasal polyps in the setting of severe chronic rhinosinusitis (18). However, those with greater type 2 inflammation often have concomitant CRSwNP, so it is not surprising that clinicians chose mepolizumab for those with this comorbidity (19). Since the people started on mepolizumab have a higher incidence of CRSwNP in this study, these people likely have greater Th2 inflammation which suggests that the population on mepolizumab, regardless of when they discontinue the medication, are going to have more severe asthma at baseline than the people placed on other biologics, which is supported by the higher use of prednisone (62% vs 36%, P <

0.001). Our sub-analysis of the cohort with CRSwNP demonstrated that there was no difference in the

people that stayed on mepolizumab and those that discontinued it early (Table 3).

A second limitation is that the individuals in Group A have either milder asthma or better controlled at

baseline as they have a higher baseline ACT score and a better baseline FEV_1 (72% vs 62%

predicted, $P = 0.07$). It is difficult to ascertain just based on this observational review whether the

participants of Group B have asthma that is severe and uncontrolled or just uncontrolled at baseline.

Finally, since this was a real-world study, there is also attrition between the baseline visit and visit 18,

which reduces the power of our study. If an individual left the study to receive their asthma

management at another facility, their information was not recorded. This further reduces the power of

our study. It is remarkable that given the limitations, we still were able to corroborate the findings of

DREAM, MENSA, MUSCA, SIRIUS, and REALITI-A, and we were also able to find a strong

relationship between ACT score and mepolizumab response.

In conclusion, upto 17% of patients discontinue therapy within 6 months, with male sex and low ACT

score increasing risk of early discontinuation.. One mechanism for low ACT scores in the people that

discontinue mepolizumab early could be related to altered gut microbiome in the setting of obesity

with an altered immune response favoring low Th2 pathways that would be less responsive to

biologics targeting Th2 high pathways, despite having a high baseline eosinophil count.Further

studies are needed to determine which, if any, biologics might perform better in those people who

suffer with severe asthma and poor control.

Table 1. Baseline characteristics of people on mepolizumab therapy compared to the baseline characteristics of individuals started on any other biologic agent. Participants on mepolizumab have a higher incidence of nasal polyps, sinusitis, and prednisone dependence.

Definition of abbreviations: ACT = Asthma Control Test; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; BMI = Body Mass Index; GERD = Gastroesophageal Reflux Disease; CAD = Coronary Artery Disease; CHF = Congestive Heart Failure; Pre-FEV$_1$ = Pre-Forced Expiratory volume in 1 second; WBC = White Blood Cell Count; IQR = Interquartile Range

	Mepolizumab	Other Biologics	P-Value
n	157	66	
Age (median [IQR (interquartile range)])	53 [18]	51 [21]	0.168
Sex = Male (%)	49 (31.2%)	29 (43.9%)	0.077
ACT total (median [IQR])	12 [9]	11 [7]	0.1
Race %			0.126
White	128 (81.5%)	46 (69.7%)	
African American	21 (13.4%)	10 (15.2%)	
Other	8 (5.1%)	8 (12.1%)	
SBP (median [IQR])	133 [19]	127 [28]	0.157
DBP (median [IQR])	76 [17]	77 [13]	0.905
Pulse (median [IQR])	81.5 [19.8]	83 [15.8]	0.845
BMI (median [IQR])	32.1 [9.7]	30 [12.1]	0.171
Age Asthma Diagnosis (median [IQR])	32 [34.5]	25 [36.5]	0.782
History of Nasal Polyps	**69 (44%)**	**16 (24.2%)**	**<0.05**

History of Sinusitis	112 (71.3%)	30 (45.5%)	<0.001
History of Vocal Cord Dysfunction	12 (7.6%)	6 (9.1%)	0.871
History of Pneumonia	114 (72.6%)	44 (66.7%)	0.392
History of Supplemental Oxygen	20 (12.7%)	6 (9.1%)	0.603
History of GERD	95 (60.5%)	30 (45.5%)	0.055
Diabetes	27 (17.2%)	11 (16.7%)	0.999
Hypertension	61 (38.9%)	22 (33.3%)	0.591
CAD	6 (3.8%)	4 (6.1%)	0.688
CHF	7 (4.6%)	1 (1.5%)	0.497
Pre-FEV$_1$ % (median [IQR])	70 [33]	64 [35.7]	0.823
WBC	9.3 [4.0]	8.5 [4.2]	0.253
Absolute Eosinophils (median [IQR])	0.3 [0.5]	0.2 [0.4]	0.124
Absolute Neutrophils (median [IQR])	6 [4.3]	5.5 [4.6]	0.653
Platelets (median [IQR])	280 [101.8]	289 [70.5]	0.681
Prednisone at Baseline visit	98 (62%)	24 (36%)	< 0.001

Table 2. Characteristics of Group A and Group B are delineated in this table. Those in Group B have remarkably lower baseline ACT score.

Definition of abbreviations: ACT = Asthma Control Test; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; BMI = Body Mass Index; GERD = Gastroesophageal Reflux Disease; CAD = Coronary Artery Disease; CHF = Congestive Heart Failure; Pre-FEV$_1$ = Pre-Forced Expiratory volume in 1 second; WBC = White Blood Cell Count; IQR = Interquartile Range; IBD= Irritable Bowel Disease.

	Group A	Group B	P- Value
n	129	28	
Age (median [IQR])	53 [19]	53 [15]	0.849
Sex = Male (%)	36 (30%)	13 (36%)	0.071
ACT total (median [IQR])	13 [9]	9 [4]	< 0.05
Race%			0.497

White	103 (79.8%)	25 (89.3%)	
African American	19 (14.7%)	2 (7.1%)	
Other	7 (0.8%)	1 (3.6%)	
SBP (median [IQR])	132 [18]	133.5 [23]	0.418
DBP (median [IQR])	75 [15]	83 [18.3]	0.058
Pulse (median [IQR])	81.5 [21.5]	81.5 [16.3]	0.757
BMI (median [IQR])	31.9 [9.8]	33.2 [10.2]	0.262
Age Asthma Diagnosis (median [IQR])	34.50 [33.3]	21 [31]	0.182
History of Nasal Polyps	58 (45%)	11 (39.3%)	0.896
History of Sinusitis	90 (69.8%)	22 (78.6%)	0.23
History of Vocal Cord Dysfunction	11 (8.5%)	1 (3.6%)	0.68
History of Pneumonia	99 (71.2%)	17 (68%)	0.856
History of Supplemental Oxygen	15 (11.6%)	5 (17.8%)	0.531
History of GERD	78 (60.5%)	17 (60.7%)	0.874
History of IBD	3 (2.3%)	0 (0)	0.917
Diabetes	22 (17.1%)	5 (17.9%)	0.999
Hypertension	54 (41.9%)	7 (25%)	0.175
CAD	6 (4.7%)	0 (0)	0.546
CHF	6 (4.7%)	1 (3.6%)	0.999
Pre-FEV$_1$ % (median [IQR])	71.7 [31.5]	61.5 [34.5]	0.068
WBC (median [IQR])	9.2 [3.7]	10.6 [6.3]	0.293
Absolute Eosinophils (median [IQR])	0.3 [0.46]	0.2 [0.38]	0.228
Absolute Neutrophils (median [IQR])	5.8 [4.4]	7 [4.6]	0.155
Platelets (median [IQR])	282 [102]	264 [79.3]	0.531
Prednisone at Baseline Visit	77 (59.7%)	21 (75%)	0.244

Table 3. Group A demonstrates the baseline characteristics of people with nasal polyps that stay on mepolizumab. Group B demonstrates the baseline characteristics of the people with nasal polyps that have to be taken off mepolizumab. There is no observable difference between the two groups.

Definition of abbreviations: ACT = Asthma Control Test; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; BMI = Body Mass Index; GERD = Gastroesophageal Reflux Disease; CAD = Coronary Artery Disease; CHF = Congestive Heart Failure; Pre-FEV$_1$ = Pre-Forced Expiratory volume in 1 second; WBC = White Blood Cell Count; IQR = Interquartile Range; IBD= Irritable Bowel Disease.

	Group A	Group B	*P*- Value
n	58	11	
Age (median [IQR])	52.5 [17]	54 [14]	0.961
Sex = Female (%)	41 (70.1%)	6 (54%)	0.420
ACT total	14.5 [8]	9 [6.5]	0.055
Race%			0.252
White	46 (79%)	11 (100%)	
African American	10 (17.2%)	0 (0%)	
Other	2 (3.4%)	0 (0%)	
SBP (median [IQR])	133 [14.5]	131 [9]	0.477
DBP (median [IQR])	76 [12.5]	85 [12.5]	0.170
Pulse (median [IQR])	81 [21.5]	83 [16]	0.680
BMI (median [IQR])	31 [12]	32.5 [6.8]	0.513
Age at asthma diagnosis (median [IQR])	32 [32]	28 [20.5]	0.868
History of vocal cord dysfunction	5 (8.6%)	1 (9.1%)	0.999
History of Pneumonia	43 (74.1%)	7 (63.6%)	0.591
History of Supplemental Oxygen	7 (12%)	1 (9.1%)	0.999
History of GERD	35 (60.3%)	8 (72.8%)	0.439
Hx of Diabetes	8 (14.8%)	3 (27.3%)	0.519
Hx of Hypertension	19 (32.8%)	2 (18.2%)	0.545
CAD	2 (3.4%)	0 (0%)	0.999
CHF	1 (1.7%)	0 (0%)	0.999
pre-FEV1% (median [IQR])	69 [34]	54 (39.5%)	0.298
WBC (median [IQR])	8.9 [3.7]	11.45 [6.3]	0.193
Absolute Eosinophils (median [IQR])	0.38 [0.5]	0.26 [0.5]	0.542
Absolute Neutrophils (median [IQR])	5.88 [3.9]	8.3 [7.7	0.180
Platelets (median [IQR])	264 [104]	241 [62.8]	0.635

Table 4. Table 4 analyzes Group B compared to Group A after those excluded due to side effects were added back to the cohort. Group B has a higher number of males and also has a lower ACT score compared to group A at the baseline visit.

Definition of abbreviations: ACT = Asthma Control Test; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; BMI = Body Mass Index; GERD = Gastroesophageal Reflux Disease; CAD = Coronary Artery Disease; CHF = Congestive Heart Failure; Pre-FEV$_1$ = Pre-Forced Expiratory volume in 1 second; WBC = White Blood Cell Count; IQR = Interquartile Range; IBD= Irritable Bowel Disease.

	Group A	Group B	*P*- Value
n	129	43	
Age (median [IQR])	53 [19]	53.5 [14]	0.909
Sex = Female (%)	**76 (72%)**	**23 (53%)**	**< 0.05**
ACT total	**13 [9]**	**10 [7]**	**< 0.05**
Race%			0.982
White	103 (79.8 %)	34 (81%)	
African American	19 (14.7%)	6 (14.3%)	
Other	7 (5.4%)	2 (4.8%)	
SBP (median [IQR])	132 [15]	133 [16.5]	0.342
DBP (median [IQR])	75 [15]	85 [20]	0.283
Pulse (median [IQR])	81.5 [21.5]	82 [17.5]	0.535
BMI (median [IQR])	31.9 [12]	32.3 [11.43]	0.300
Age at asthma diagnosis (median [IQR])	32 [32]	28 [35]	0.340
History of vocal cord dysfunction	5 (8.6%)	2 (5%)	0.695
History of Pneumonia	**43 (74.1%)**	**24 (60%)**	**< 0.05**
History of Supplemental Oxygen	7 (12%)	6 (14.6%)	0.839
History of GERD	35 (60.3%)	27 (67.5%)	0.612
Hx of Diabetes	8 (14.8%)	10 (24.4%)	0.439
Hx of Hypertension	19 (32.8%)	14 (34.1%)	0.465
CAD	2 (3.4%)	0 (0%)	0.351
CHF	1 (1.7%)	6 (4.7%)	0.873
pre-FEV1% (median [IQR])	69 [34]	71.70 [31.5]	0.360
WBC (median [IQR])	8.9 [3.7]	10.2 [6.4]	0.208
Absolute Eosinophils (median [IQR])	0.38 [0.5]	0.2 [0.4]	0.172
Absolute Neutrophils (median [IQR])	5.88 [3.9]	6.93 [4.6]	0.088
Platelets (median [IQR])	264 [104]	263.5 [93.3]	0.471
Prednisone at Baseline Visit	77(61.1%)	28 (65.1%)	0.252

Figure 1. Flowchart delineates information collected at visits at baseline, 3 months, 6 months, 12 months, and 18 months. Questionnaires were collected at every visit. ACT, medication use, and spirometry results were also recorded at every visit.

Definitions: F$_E$NO = fractional exhaled nitric oxide; CBC = Complete Blood Count; ACT = Asthma Control Test

Figure 2A. The registry has 199 people initiated on mepolizumab between the years of 2016 and 2022. 27 people were removed for having only one visit recorded within the database. 15 people were removed for stopping mepolizumab for reasons other than clinical failure. Of the remaining 157 participants, 129 people are clinically considered mepolizumab responders as defined by an asthma specialist. Figure 2B is a pie chart demonstrating the reasons people were removed from this study. Most people that were removed had only a single visit recorded or were lost to follow up.

A

*15 people are removed as each of these discontinued mepolizumab for reasons other than clinical failure.

B

Figure 3. The number of participants per visit is shown in this bar graph which shows attrition over subsequent visits.

Figure 4. Panel A demonstrates median ACT scores. Each visit has an increase in ACT scores. Panel B demonstrates the greatest increase in median FEV₁% occurs between visit 1 and visit 3. Panel C shows the decrease in prednisone use for participants while on mepolizumab. The asterisk (*) is for $P < 0.05$.

Figure 5. Time to discontinuation of mepolizumab or censorship between the two cohorts is different with *P* < 0.05. The Kaplan – Meier curve demonstrates the average time someone from Group B is on mepolizumab and the average time to censorship for Group A. Group B stay on mepolizumab for a mean of 5.8 months (standard deviation [SD] 4.2 months). Group A are on mepolizumab for a mean of 12.3 months (SD 4.6 months) to the time of censorship. The tick marks for group A represent when our database stops recording the participant's information though they may still be on mepolizumab.

Figure 6A This graph depicts the mean ACT score with standard deviation of Group A, which is the group of people that remained on mepolizumab. Through subsequent visits, the mean ACT score of the group significantly improves from the baseline ACT score. Graph 6B demonstrates the mean ACT score for Group B does not significantly change between the baseline visit and 12 months.

Figure 7. Group B present with a remarkably lower ACT score prior to starting mepolizumab therapy compared to responders (9 [IQR 4], 13 [IQR9]).

Definitions: ACT = Asthma Control Test

Figure 8. Receiver operating curve (ROC) for ACT score in all participants started on mepolizumab showed an ACT cutoff score of 13.

Definitions: ROC = Receiver Operating Curve; AUC = Area Under the Curve

Figure 9. For a participant who has an ACT score of 13, the odds ratio of discontinuing mepolizumab therapy is 6.64 (95% CI, 2.1 – 26.0). For a male, the odds ratio of discontinuing mepolizumab therapy is 3.39 (95% CI, 1.1 – 11.2).

Definitions: ACT = Asthma Control Test; BMI = Body Mass Index; F_ENO = fractional exhaled nitric oxide

	Odds Ratio	CI	P - Value
ACT < 13	6.64	2.1, 26.0	0.003
Male Sex	3.39	1.1, 11.2	0.039
Age	0.97	0.9, 1.0	0.238
BMI	1.01	0.9, 1.1	0.808
F_ENO	0.80	0.4, 1.5	0.466
	0.29	0.02, 1.9	0.336
Eosinophils			

1.   Lopez-Tiro J, Contreras-Contreras A, Rodriguez-Arellano ME, Costa-Urrutia P. Economic burden of severe asthma
treatment: A real-life study. World Allergy Organ J. 2022;15(7):100662.
2.   Venkatesan P. 2023 GINA report for asthma. Lancet Respir Med. 2023.
3.   Reibman J, Tan L, Ambrose C, Chung Y, Desai P, Llanos JP, et al. Clinical and economic burden of severe asthma
among US patients treated with biologic therapies. Ann Allergy Asthma Immunol. 2021;127(3):318-25 e2.
4.   Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al. Characterization of Severe Asthma
Worldwide: Data From the International Severe Asthma Registry. Chest. 2020;157(4):790-804.
5.   Pavord ID, Bel EH, Bourdin A, Chan R, Han JK, Keene ON, et al. From DREAM to REALITI-A and beyond:
Mepolizumab for the treatment of eosinophil-driven diseases. Allergy. 2022;77(3):778-97.
6.   Fala L. Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance
Treatment of Patients with Severe Asthma. Am Health Drug Benefits. 2016;9(Spec Feature):106-10.
7.   Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: The changing
landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf. 2020;29(10):1201-12.
8.   Kavanagh JE, d'Ancona G, Elstad M, Green L, Fernandes M, Thomson L, et al. Real-World Effectiveness and the
Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. Chest. 2020;158(2):491-500.
9.   van Toor JJ, van der Mark SC, Kappen JH, In 't Veen J, Braunstahl GJ. Mepolizumab add-on therapy in a real world
cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. J Asthma. 2021;58(5):651-8.
10.   Kroes JA, Alfonso-Cristancho R, Bansal AT, Berret E, Bieksiene K, Bourdin A, et al. Evaluation of real-world
mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis. ERJ
Open Res. 2023;9(2).
11.   Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, et al. Mepolizumab effectiveness and
identification of super-responders in severe asthma. Eur Respir J. 2020;55(5).
12.   Pertzov B, Unterman A, Shtraichman O, Shitenberg D, Rosengarten D, Kramer MR. Efficacy and safety of
mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. J Asthma. 2021;58(1):79-84.
13.   McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in Asthma. Am J Respir Crit Care Med.
2019;199(4):433-45.
14.   Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, et al. Biomarkers for severe eosinophilic asthma.
J Allergy Clin Immunol. 2017;140(6):1509-18.
15.   Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. Eur Respir Rev. 2021;30(162).
16.   Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018;141(4):1169-79.
17.   Litonjua AA, Sparrow D, Celedon JC, DeMolles D, Weiss ST. Association of body mass index with the development
of methacholine airway hyperresponsiveness in men: the Normative Aging Study. Thorax. 2002;57(7):581-5.
18.   Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic
rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir
Med. 2021;9(10):1141-53.
19.   Pelaia C, Pelaia G, Maglio A, Tinello C, Gallelli L, Lombardo N, et al. Pathobiology of Type 2 Inflammation in
Asthma and Nasal Polyposis. J Clin Med. 2023;12(10).